IDDI & Roche Identify DFS As Way Forward In Early Breast Cancer


Applied Clinical Trials

Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.  

To learn more about their findings, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.